Department of Computer, Control and Management Engineering "Antonio Ruberti" (DIAG), Sapienza University of Rome, Via Ariosto 25, 00185 Rome, Italy.
Institute for Systems Analysis and Computer Science "Antonio Ruberti", National Research Council, Via dei Taurini 19, 00185 Rome, Italy.
Int J Mol Sci. 2022 Mar 28;23(7):3703. doi: 10.3390/ijms23073703.
Drug repurposing strategy, proposing a therapeutic switching of already approved drugs with known medical indications to new therapeutic purposes, has been considered as an efficient approach to unveil novel drug candidates with new pharmacological activities, significantly reducing the cost and shortening the time of de novo drug discovery. Meaningful computational approaches for drug repurposing exploit the principles of the emerging field of Network Medicine, according to which human diseases can be interpreted as local perturbations of the human interactome network, where the molecular determinants of each disease (disease genes) are not randomly scattered, but co-localized in highly interconnected subnetworks (disease modules), whose perturbation is linked to the pathophenotype manifestation. By interpreting drug effects as local perturbations of the interactome, for a drug to be on-target effective against a specific disease or to cause off-target adverse effects, its targets should be in the nearby of disease-associated genes. Here, we used the network-based proximity measure to compute the distance between the drug module and the disease module in the human interactome by exploiting five different metrics (minimum, maximum, mean, median, mode), with the aim to compare different frameworks for highlighting putative repurposable drugs to treat complex human diseases, including malignant breast and prostate neoplasms, schizophrenia, and liver cirrhosis. Whilst the standard metric (that is the minimum) for the network-based proximity remained a valid tool for efficiently screening off-label drugs, we observed that the other implemented metrics specifically predicted further interesting drug candidates worthy of investigation for yielding a potentially significant clinical benefit.
药物重定位策略,提出了一种治疗性的转换,即将已经批准的具有已知医疗适应症的药物用于新的治疗目的,被认为是揭示具有新药理活性的新型药物候选物的有效方法,显著降低了成本并缩短了从头发现药物的时间。有意义的药物重定位计算方法利用了新兴的网络医学领域的原理,根据该原理,人类疾病可以被解释为人类相互作用网络的局部扰动,其中每个疾病的分子决定因素(疾病基因)不是随机分散的,而是共定位在高度相互连接的子网络(疾病模块)中,其扰动与表型表现相关。通过将药物作用解释为相互作用网络的局部扰动,对于一种药物要针对特定疾病有效或引起脱靶不良反应,其靶点应该在与疾病相关的基因附近。在这里,我们使用基于网络的邻近度度量来计算人类相互作用网络中药物模块和疾病模块之间的距离,利用了五种不同的度量(最小、最大、平均、中位数、模式),旨在比较不同的框架,以突出可能具有重新定位用途的药物来治疗复杂的人类疾病,包括恶性乳腺和前列腺肿瘤、精神分裂症和肝硬化。虽然基于网络的邻近度的标准度量(即最小度量)仍然是有效筛选非标签药物的有效工具,但我们观察到,其他实施的度量特别预测了进一步有趣的药物候选物,值得进一步研究,以产生潜在的显著临床益处。